Enzyme evolution can be used to take a wild-type enzyme that is in some way unsuitable for a bioprocess of interest and create a strain with enhanced capabilities. This iterative process is based on the design-build-test-learn (DBTL) cycle,1 and can be used…
Cell line development is a critical aspect of biotechnology and pharmaceutical research, and plays an important role in Ingenza’s CRDMO services. The process involves establishing and maintaining genetically identical mammalian cells in culture for use in a variety of processes, such…
Industrial biotech specialist Ingenza is delighted to announce that it is collaborating with Cellugy to accelerate the development of its innovative platform for producing biofabricated cellulose. This technology will provide a sustainable alternative to fossil-based petrochemicals in various industrial applications, starting with personal care…
The performance and economics of any bioprocess are significantly impacted by the choice of host platform. Ingenza’s diverse range of bacterial, yeast and mammalian production platforms is an excellent foundation for biomanufacturing development. In this white paper, Rita Cruz, Section Head of…
Ingenza has a comprehensive suite of validated analytical methods and assays that can be readily employed to fully characterise both small molecules and biologics targets throughout all stages of bioprocess development and optimisation. We aim to deliver high quality results…
Thanks for joining us – if you would like to re-watch the webinar, the video has been made available below to watch again. Discover how Ingenza masters the production of complex proteins with viable, scalable and cost-effective bioprocesses. In this…
The biopharmaceutical sector is expanding twice as fast as traditional drug manufacturing, and currently accounts for 20 percent of the pharmaceutical industry.1,2 Biotechnology companies are therefore under increasing pressure to maintain a rapid pace of development, while providing trackable documentation to…
Scottish CRDMO Ingenza has secured innovation funding to adapt its codABLE™ machine learning platform to precisely control recombinant protein expression in the industrial yeast Pichia pastoris. This game-changing project will accelerate the development of therapeutics, enzymes and other proteins by harnessing machine learning to…
Recombinant protein production is an important technique for generating large quantities of proteins in a variety of pharmaceutical, agricultural and industrial applications. It is widely used in the development and manufacture of drugs – such as insulin, growth factors and…
Edinburgh, Scotland – Ingenza, a dynamic CDMO and leader in engineering biology, is pleased to announce its strategic partnership with Opvia, a Quality Management Systems (QMS) provider. This partnership is driven by Ingenza’s commitment to enhance and centralise its quality…